Még nem toboroz
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
NCT07791732· 3. fázis· Daiichi Sankyo· Forrás
Még nem toboroz
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· 2. fázis· UNICANCER· Forrás
Toboroz
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· 3. fázis· Institut Gustave Roussy· Forrás
Még nem toboroz
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
2024-520140-42-00· 3. fázis· Institut Gustave Roussy· Forrás
Toboroz
Early detection of triple negative breast cancer relapse (CUPCAKE)
2022-501562-22-01· 2. fázis· Institut Curie· Forrás
Toboroz
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253· 3. fázis· AstraZeneca· Forrás
Toboroz
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
NCT06656598· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients
NCT06846346· 2. fázis· Unicancer· Forrás
Toboroz
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· 3. fázis· AstraZeneca· Forrás
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· UNICANCER· Forrás
Toboroz
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a multicentre phase II randomized trial (PIPOX02)
2024-514560-10-00· 2. fázis· Institut De Cancerologie De L Ouest· Forrás
Toboroz
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· 3. fázis· UNICANCER· Forrás
Toboroz
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
NCT06245356· 2. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485· 3. fázis· Celgene· Forrás
Toboroz
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864· 2. fázis· UNICANCER· Forrás
Toboroz
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.
2022-501315-13-00· 3. fázis· Centre Leon Berard· Forrás
Toboroz
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)
2023-503326-39-00· 3. fázis· Institut Gustave Roussy· Forrás
Toboroz
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT06725368· 2. fázis· Centre Paul Strauss· Forrás
Toboroz
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
2023-503675-24-00· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS
NCT06715241· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Toboroz
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· 3. fázis· UNICANCER· Forrás
Toboroz
FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage
NCT05168839· 4. fázis· Centre Hospitalier Regional Universitaire· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· 3. fázis· Gilead Sciences· Forrás
Toboroz
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI
2023-505298-34-00· 2. fázis· Unicancer· Forrás
Toboroz
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
NCT06195709· 3. fázis· Institut Curie· Forrás
Toboroz
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· 3. fázis· Institut Gustave Roussy· Forrás
Toboroz
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT05856695· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326· 2. fázis· Genentech, Inc.· Forrás
Toboroz
A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06))
2023-505040-19-00· 2. fázis· Institut Gustave Roussy· Forrás
Fut, nem toboroz
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
NCT05219318· 3. fázis· University Hospital, Bordeaux· Forrás
Toboroz
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
NCT05476939· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Fut, nem toboroz
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
NCT05200481· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
2024-518244-20-01· 2. fázis· Queen Mary University Of London· Forrás
Toboroz
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast Cancer
NCT04784714· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
NCT03806309· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Fut, nem toboroz
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NCT04621188· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· 1/2. fázis· University of Birmingham· Forrás
Fut, nem toboroz
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, high burden disease: chemotherapy and combination of hormonotherapy with abemaciclib.
NCT04158362· 3. fázis· Unicancer· Forrás
Toboroz
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632· 1. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
NCT03875781· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Fut, nem toboroz
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
NCT03842982· 3. fázis· Centre Oscar Lambret· Forrás
Fut, nem toboroz
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
NCT03697850· 2. fázis· UNICANCER· Forrás
Fut, nem toboroz
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· 3. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Showing 50 of 57.